The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

A global biotech is axing more of its Greater Washington workforce, eliminating nearly 100 positions across multiple waves of ...

BioNTech stock, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained ...

Türeci co-founded BioNTech, a German company that partnered with pharmaceutical giant Pfizer to develop the first U.S.-authorized COVID-19 vaccine.

BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...

BioNTech, a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the ...